By Fineline Cube 
China-headquartered TransThera Sciences (Nanjing) Inc. is preparing for an initial public offering (IPO) of 15.281 million shares on the Hong Kong Stock Exchange. The offering includes 10% allocated to the Hong Kong public and 90% to international placement, with an over-allotment option of 15%. The shares are priced at HKD 13.15 (USD 1.7) each, with trading set to commence on June 23, 2025.
Company Overview
TransThera Sciences, a clinical-stage biopharmaceutical company, focuses on developing innovative small molecule therapies for oncology, inflammation, and cardiometabolic diseases. The company has a pipeline of six clinical-stage candidates and one preclinical asset.
Pipeline Highlights
The company’s flagship product, tinengotinib, is a multiple tyrosine kinase (MTK) inhibitor targeting FGFR/VEGFR, JAK, and Aurora. It is currently undergoing pivotal/regulatory studies in previously treated cholangiocarcinoma (CCA). Tinengotinib is also being investigated for metastatic castration-resistant prostate cancer (mCRPC), breast cancer, biliary tract cancers (BTC), and pan-FGFR solid tumors. Phase II studies have been completed, and the company plans to evaluate its potential in combination with cadonilimab or ivonescimab for hepatocellular carcinoma (HCC) in Phase II trials.
IPO Details
The IPO has secured five cornerstone investors, including Akeso Biopharma, with total commitments of approximately HKD 130 million (USD 17 million). The net proceeds from the offering are estimated at HKD 161 million (USD 21 million). Ten percent of the proceeds (HKD 16.1 million) will be allocated to general working capital, while 90% (HKD 145 million) will fund the ongoing global Phase III trial of tinengotinib as a monotherapy for CCA.-Fineline Info & Tech